Figure 4.

Evaluation of the immunogenicity of Rubella TAKAHASHI in combination with MMR vaccine (AIK-C, S#12,) strains in adult volunteers.

A. After receiving the vaccine, among the adult volunteers aged 17-37, 14.2% of cases showed the effect of a booster dose, and the antibody titer increased. In a similar vein, in 33.9% of cases, the increase has doubled, and the antibody titer has remained constant in 41.3% of subjects. B. In the with no history of infection or vaccination (Nonimmune), in 100% of cases, the average geometric titer was increased to 2.5 based on Log 2. As depicted in Figure B, 97.9% of cases reported a history of rubella disease or vaccination who were in the immune group and were seropositive before receiving the vaccine. In this study, the results were evaluated by the HI test.